[引用][C] Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) …
Optimizing the treatment for advanced non–small-cell lung cancer with mutated epidermal growth factor receptor in low-income countries: a review
… Osimertinib was the only TKI that showed efficacy against the … Therefore, it was approved as
a third-line treatment in 2003. … ) compared gefitinib with placebo and found no differences in …
a third-line treatment in 2003. … ) compared gefitinib with placebo and found no differences in …
… , double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer–The FALUCA study
… efficacy and safety of fruquintinib in patients with advanced … for fruquintinib compared with
placebo as third-line therapy in … that fruquintinib in combination with gefitinib had an ORR of …
placebo as third-line therapy in … that fruquintinib in combination with gefitinib had an ORR of …
[HTML][HTML] Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase …
… the molecular biology of non-small cell lung cancer (NSCLC) … in the next line of therapy
(namely, third line or fourth line, depending … regimens with proven efficacy for this population. The …
(namely, third line or fourth line, depending … regimens with proven efficacy for this population. The …
[HTML][HTML] Targeted therapy for older patients with non-small cell lung cancer: Systematic review and guidelines from the French Society of Geriatric Oncology (SoFOG) …
L Greillier, M Gauvrit, E Paillaud, N Girard, C Montégut… - Cancers, 2022 - mdpi.com
… treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR
mutation: gefitinib … phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/…
mutation: gefitinib … phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/…
Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
… comparing afatinib to gefitinib and erlotinib to gefitinib. We used … , while erlotinib is only
publicly funded for second- and third-line … efficacy and safety profiles associated with osimertinib …
publicly funded for second- and third-line … efficacy and safety profiles associated with osimertinib …
… medical costs of epidermal growth factor receptor (EGFR) mutations in patients with advanced EGFR mutation-positive non-small cell lung cancer treated with afatinib …
G Mountzios, S Lampaki, GA Koliou… - Lung Cancer: Targets …, 2021 - Taylor & Francis
… -line treatment in five patients (8.5%) and as third-line and … -line treatment, based on its
superior efficacy as compared to … it exerts higher activity than erlotinib or gefitinib, albeit some …
superior efficacy as compared to … it exerts higher activity than erlotinib or gefitinib, albeit some …
[HTML][HTML] … treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium …
K Cuppens, L Lodewyckx, I Demedts… - Drugs-real world …, 2021 - Springer
… characterized by lower sensitivity compared with tests on tissue … Secondary outcomes were
analyzed on the ‘efficacy’ … -line treatment, 2L second-line treatment, 3L third-line treatment, …
analyzed on the ‘efficacy’ … -line treatment, 2L second-line treatment, 3L third-line treatment, …
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors …
H Hayashi, S Sugawara, Y Fukuda, D Fujimoto… - Clinical Cancer …, 2022 - AACR
… cytotoxic chemotherapy in patients with metastatic EGFR-mutated non–small cell lung cancer
… II trial to evaluate the efficacy and safety of nivolumab compared with the combination of …
… II trial to evaluate the efficacy and safety of nivolumab compared with the combination of …
[HTML][HTML] Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma
R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
… EGFR‑mutated non‑small cell lung cancer (NSCLC). Due to the … trial compared the efficacy
of afatinib and gefitinib for the … to be associated with gefitinib or erlotinib resistance. Due to the …
of afatinib and gefitinib for the … to be associated with gefitinib or erlotinib resistance. Due to the …